Cabozantinib for Progressive HCC Post-first-line Immuno-oncologic Combination Therapy

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

June 30, 2028

Study Completion Date

June 30, 2028

Conditions
Hepatocellular Carcinoma (HCC)
Interventions
DRUG

Cabozantinib

All patients will be treated with cabozantinib at 60 mg once daily.

Trial Locations (9)

100

National Taiwan University Hospital, Taipei

104

Mackay Memorial Hospital, Taipei

407

Taichung Veterans General Hospital, Taichung

Unknown

Chang-Gung Memorial Hospital, Kaohsiung, Kaohsiung City

China Medical University Hospital, Taichung

National Cheng-Kung University Hospital, Tainan City

Taipei Veterans General Hospital, Taipei

Tri-Service General Hospital, Taipei

Chang Gung Memorial Hospital (Lin-Kou),, Taoyuan District

All Listed Sponsors
collaborator

National Taiwan University Hospital

OTHER

collaborator

Taipei Veterans General Hospital, Taiwan

OTHER_GOV

collaborator

Tri-Service General Hospital

OTHER

collaborator

Mackay Memorial Hospital

OTHER

collaborator

Chang Gung Memorial Hospital

OTHER

collaborator

China Medical University Hospital

OTHER

collaborator

Taichung Veterans General Hospital

OTHER

collaborator

National Cheng-Kung University Hospital

OTHER

lead

National Health Research Institutes, Taiwan

OTHER